WCN26-6877 Targeted-Release Formulation of Budesonide in Real-World Follow-Up Study of Patients with IgA Nephropathy

Read full text Summarise with VIRAT
Authors: Yan Ouyang, Tong Yiming, Zhengying Fang, Xiaolin Lin, Hongyan Xie, Xiaoxia Pan, Jingyuan Xie
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide and is especially common in East Asia. Although supportive treatments have improved, many patients still progress to end-stage renal disease. Nefecon, a targeted-release formulation of budesonide designed to act on the gut-associated lymphoid tissue (GALT), has been shown in clinical trials to reduce proteinuria and slow kidney function decline. However, real-world data on its effectiveness in Chinese patients are still limited.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Vasculitis and related conditions

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104511–104511
Publication date
25 March 2026
Language
EN